Lunai Competitors

Stocks . USA . 
Stock . Lunai Bioworks
LNAI Stock   0.99  0.04  3.88%   
Lunai Bioworks competes with Eterna Therapeutics, Moleculin Biotech, BioLineRx, GeoVax Labs, and Adlai Nortye; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Lunai Bioworks competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Lunai Bioworks to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Lunai Bioworks Correlation with its peers.
For more detail on how to invest in Lunai Stock please use our How to Invest in Lunai Bioworks guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Lunai Bioworks competition on your existing holdings.
  
Build AI portfolio with Lunai Stock
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.050.9910.57
Details
Intrinsic
Valuation
LowRealHigh
0.050.9110.49
Details
Naive
Forecast
LowNextHigh
0.020.9410.52
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.831.131.43
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Lunai Bioworks. Your research has to be compared to or analyzed against Lunai Bioworks' peers to derive any actionable benefits. When done correctly, Lunai Bioworks' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Lunai Bioworks.

Lunai Bioworks Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Lunai Bioworks and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Lunai and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Lunai Bioworks does not affect the price movement of the other competitor.

High positive correlations

GOVX
+ 0.88
MBRX
ICU
+ 0.81
GOVX
GOVX
+ 0.79
BLRX
ICU
+ 0.79
BLRX
ICU
+ 0.76
MBRX
BLRX
+ 0.71
MBRX
  

High negative correlations

LPCN
- 0.73
GOVX
LPCN
- 0.67
MBRX
LPCN
- 0.6
ICU
LPCN
- 0.59
THAR
ICU
- 0.55
ADAP
LPCN
- 0.39
BLRX

Risk-Adjusted Indicators

There is a big difference between Lunai Stock performing well and Lunai Bioworks Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Lunai Bioworks' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ADAP  12.67 (1.39) 0.00  1.87  0.00 
 0.00 
 49.18 
(18.18)
 120.50 
ERNA  4.77  0.29  0.07  0.25  4.65 
(5.66)
 13.33 
(7.41)
 51.97 
MBRX  5.03 (1.33) 0.00 (1.39) 0.00 
 0.00 
 9.76 
(11.73)
 41.63 
BLRX  2.82 (0.39) 0.00 (0.30) 0.00 
 0.00 
 5.21 
(5.31)
 13.04 
GOVX  5.09 (1.76) 0.00 (0.59) 0.00 
 0.00 
 8.11 
(13.16)
 48.23 
ANL  4.17 (0.13) 0.00 (0.07) 0.00 
 0.00 
 9.09 
(8.48)
 31.06 
ICU  4.68 (1.32) 0.00 (1.14) 0.00 
 0.00 
 9.68 
(9.80)
 33.33 
THAR  4.60 (0.02) 0.00  0.09  0.00 
 0.00 
 8.89 
(9.64)
 35.56 
APLM  7.89  0.78  0.05 (0.24) 9.08 
(11.41)
 17.50 
(17.72)
 96.36 
LPCN  3.17  0.97  0.28 (1.21) 2.26 
(3.88)
 12.67 
(4.48)
 18.81 
All Fundamental Data

Lunai Bioworks Competitive Analysis

The better you understand Lunai Bioworks competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Lunai Bioworks' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Lunai Bioworks' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
LNAI ADAP ERNA MBRX BLRX GOVX ANL ICU THAR APLM
 3.88 
 0.99 
Lunai
 6.49 
 0.04 
Adaptimmune
 3.13 
 1.24 
Eterna
 3.49 
 4.15 
Moleculin
 4.17 
 3.00 
BioLineRx
 11.76 
 0.19 
GeoVax
 0.65 
 1.52 
Adlai
 7.69 
 0.24 
LMF
 1.61 
 2.45 
Tharimmune
 6.81 
 17.23 
Apollomics
Market Volatility
(90 Days Market Risk)
Out of control
Out of control
Abnormally volatile
Very risky
Somewhat reliable
Dangerous
Very risky
Out of control
Very risky
Risky
Market Performance
(90 Days Performance)
Weakest
Weakest
Soft
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Soft
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Hazard
Risky
Low
Risky
Fair
Risky
Risky
Risky
Risky
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Not Rated
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
N/A
4.0
3.08
10.47
4.58
9.51
N/A
0.38
N/A
N/A
Net Asset
8.23 M
245.96 M
5.27 M
16.93 M
38.91 M
8.16 M
71.27 M
4.66 M
3.72 M
13.1 M
Profit Margin
N/A
-2.61
N/A
N/A
-0.45
N/A
N/A
N/A
N/A
N/A
EBITDA
(177.15 M)
(52.66 M)
(36.12 M)
(26.52 M)
3.92 M
(24.88 M)
(48.08 M)
(24.58 M)
(12.43 M)
(41.05 M)
Operating Margin
N/A
-2.21
N/A
N/A
-7.58
-7.62
-12.21
-19.56
N/A
10.07
Current Valuation
N/A
31.98 M
7.55 M
1.99 M
(812 K)
3.33 M
22.77 M
4.34 M
79.81 M
30.83 M
Price To Book
N/A
2.68
2.82
476.2
0.64
0.97
2.22
0.81
14.18
8.15
Retained Earnings
(510.46 M)
(1.09 B)
(231.54 M)
(153.37 M)
(399.83 M)
(129.36 T)
(429.32 M)
(139.56 M)
(36.9 M)
(700.82 M)
Current Asset
N/A
199.54 M
N/A
28.09 K
48.18 M
1.24 M
N/A
N/A
N/A
N/A
Beta
N/A
2.49
6.72
1.55
0.58
3.64
-0.89
-1.0
1.45
1.81
Number Of Employees
29
506
6
17
28
17
123
19
2
13
Shares Outstanding
N/A
265.05 M
7.85 M
49.5 M
4.26 M
30.06 M
31.24 M
34.1 M
35.04 M
2.14 M
Cash Flow From Operations
(7.87 M)
(73.21 M)
(15.84 M)
(23.86 M)
(43.87 M)
(24.68 M)
(51.82 M)
(16.01 M)
(10.9 M)
(28.74 M)
Total Debt
10.17 M
74.21 M
684 K
478 K
15.04 M
3.11 M
27.23 M
574 K
2.41 M
966 K
Return On Equity
N/A
-13.41
-22.64
-5.04
-0.46
-3.77
-1.03
-2.9
-2.25
-2.34
Return On Asset
N/A
-0.41
-0.89
-0.67
-0.15
-1.79
-0.33
-0.87
-1.0
-0.75
Number Of Shares Shorted
N/A
31.38 M
127.9 K
3.78 M
180.53 K
3.03 M
8.52 K
3.07 M
661.84 K
17.04 K
Book Value Per Share
N/A
-0.27
0.46
-0.24
0.008
0.17
0.69
0.34
0.85
4.41
Current Liabilities
N/A
22.66 M
N/A
772.79 K
3.14 M
126.99 K
N/A
N/A
N/A
N/A
Total Asset
8.23 M
245.96 M
5.27 M
16.93 M
38.91 M
8.16 M
71.27 M
4.66 M
3.72 M
13.1 M
Debt To Equity
N/A
0.2
0.19
0.007
0.046
0.009
2.44
N/A
N/A
N/A
Short Ratio
N/A
0.19
0.01
2.16
6.15
5.52
0.08
1.19
0.22
0.28
Target Price
N/A
0.68
3.0
6.67
26.0
9.63
9.0
1.0
5.0
2.0
Shares Owned By Institutions
N/A
31.23
6.58
4.66
1.07
11.5
0.19
7.1
3.19
0.67
Market Capitalization
N/A
14.55 M
10.05 M
22.47 M
15.18 M
5.18 M
55.72 M
8.77 M
87.26 M
44.92 M
Price To Earning
N/A
-7.73
N/A
-3.81
-3.88
-1.25
12.24
N/A
N/A
N/A
Price To Earnings To Growth
N/A
0.11
-0.03
N/A
0.2
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
0.22
10046.58
N/A
1.06
1.54
29.1
9.96
N/A
200.15
Net Income
(178.01 M)
(70.81 M)
(44.54 M)
(21.76 M)
(9.22 M)
(24.99 M)
(51.87 M)
(24.83 M)
(12.2 M)
(53.86 M)
Earnings Per Share
N/A
-0.66
56.32
-3.74
-6.0
-1.27
-1.62
-1.13
-3.68
-52.8
Shares Owned By Insiders
N/A
0.63
62.55
2.24
3.99
0.51
8.5
0.79
7.37
N/A
Revenue
N/A
178.03 M
582 K
N/A
28.94 M
3.95 M
N/A
135 K
N/A
198 K
Working Capital
(28.11 M)
123.64 M
(586 K)
(165 K)
11.7 M
4.83 M
18.7 M
(3.08 M)
1.31 M
2.87 M
Cash And Equivalents
N/A
199.67 M
19.41 M
58 M
43.15 M
30.9 M
541 K
49 K
N/A
N/A
Cash Per Share
N/A
1.22
6.6
2.03
0.9
1.25
-0.79
N/A
N/A
N/A
Gross Profit
N/A
(63.61 M)
1 K
N/A
10.23 M
(19.38 M)
1.94 M
840 K
N/A
198 K
Day Typical Price
1.01
0.0377
1.25
4.1
2.95
0.19
1.51
0.25
2.44
17.78
Accumulation Distribution
0.0755
0.17
0.0469
0.0755
0.0467
0.27
0.12
0.14
0.0442
0.1
Market Facilitation Index
0.08
0.007
0.06
0.32
0.14
0.06
0.2
0.04
0.11
1.9
Daily Balance Of Power
(0.50)
(0.36)
(0.67)
0.4375
0.8571
0.3333
(0.05)
(0.50)
(0.36)
(0.66)
Period Momentum Indicator
(0.04)
(0)
(0.04)
0.14
0.12
0.02
(0.01)
(0.02)
(0.04)
(1.26)
Rate Of Daily Change
0.96
0.94
0.97
1.03
1.04
1.12
0.99
0.92
0.98
0.93
Day Median Price
1.02
0.0385
1.25
4.08
2.93
0.19
1.51
0.26
2.44
18.05
Price Action Indicator
(0.05)
(0)
(0.03)
0.14
0.13
0.01
0.005
(0.03)
(0.01)
(1.45)
Coefficient Of Variation
(7,874)
(1,435)
1859.69
(558.71)
(1,095)
(475.25)
(10,619)
(518.97)
(12,986)
2022.53
Mean Deviation
6.45
12.67
4.77
5.03
2.82
5.09
4.17
4.68
4.6
7.89
Jensen Alpha
(0.11)
(1.39)
0.2913
(1.33)
(0.39)
(1.76)
(0.13)
(1.32)
(0.02)
0.7799
Total Risk Alpha
(0.93)
(3.13)
(0.22)
(1.87)
(0.61)
(2.23)
(0.59)
(1.80)
(0.56)
(0.44)
Sortino Ratio
N/A
N/A
0.067
N/A
N/A
N/A
N/A
N/A
N/A
0.0476
Downside Variance
N/A
N/A
23.41
N/A
N/A
N/A
N/A
N/A
N/A
142.01
Standard Deviation
9.58
20.43
7.3
7.09
3.42
7.57
6.3
6.49
6.08
12.85
Kurtosis
5.57
5.27
14.31
2.86
(0.67)
5.26
3.75
1.37
2.16
9.12
Potential Upside
12.62
49.18
13.33
9.76
5.21
8.11
9.09
9.68
8.89
17.5
Treynor Ratio
0.2942
1.87
0.245
(1.39)
(0.30)
(0.59)
(0.07)
(1.14)
0.0939
(0.24)
Maximum Drawdown
55.92
120.5
51.97
41.63
13.04
48.23
31.06
33.33
35.56
96.36
Variance
91.82
417.5
53.23
50.29
11.73
57.36
39.74
42.13
36.94
165.03
Market Risk Adjusted Performance
0.3042
1.88
0.255
(1.38)
(0.29)
(0.58)
(0.06)
(1.13)
0.1039
(0.23)
Risk Adjusted Performance
4.0E-4
(0.04)
0.0468
(0.12)
(0.06)
(0.14)
0.0023
(0.13)
0.0034
0.0441
Skewness
1.63
(0.27)
2.94
(0.89)
0.1401
(1.48)
0.8455
(0.37)
0.7583
1.75
Semi Deviation
N/A
N/A
4.65
N/A
N/A
N/A
N/A
N/A
N/A
9.08
Information Ratio
(0.02)
(0.07)
0.0444
(0.19)
(0.11)
(0.22)
(0.02)
(0.20)
(0.02)
0.0441
Value At Risk
(12.82)
(18.18)
(7.41)
(11.73)
(5.31)
(13.16)
(8.48)
(9.80)
(9.64)
(17.72)
Expected Short fall
N/A
N/A
(5.66)
N/A
N/A
N/A
N/A
N/A
N/A
(11.41)
Downside Deviation
N/A
N/A
4.84
N/A
N/A
N/A
N/A
N/A
N/A
11.92
Semi Variance
N/A
N/A
21.63
N/A
N/A
N/A
N/A
N/A
N/A
82.48

Lunai Bioworks Competition Performance Charts

Five steps to successful analysis of Lunai Bioworks Competition

Lunai Bioworks' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Lunai Bioworks in relation to its competition. Lunai Bioworks' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Lunai Bioworks in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Lunai Bioworks' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Lunai Bioworks, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Lunai Bioworks position

In addition to having Lunai Bioworks in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tips ETFs Thematic Idea Now

Tips ETFs
Tips ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Tips ETFs theme has 35 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tips ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Lunai Bioworks offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lunai Bioworks' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lunai Bioworks Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lunai Bioworks Stock:
How To Invest In Lunai
Details
Is Lunai Stock a good investment?
Details
What is Lunai Bioworks' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Lunai Bioworks Correlation with its peers.
For more detail on how to invest in Lunai Stock please use our How to Invest in Lunai Bioworks guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lunai Bioworks. If investors know Lunai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lunai Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lunai Bioworks is measured differently than its book value, which is the value of Lunai that is recorded on the company's balance sheet. Investors also form their own opinion of Lunai Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Lunai Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lunai Bioworks' market value can be influenced by many factors that don't directly affect Lunai Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Lunai Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lunai Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lunai Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY